57 results about "Tight junction" patented technology

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

To provide a novel compound capable of controlling tight junctions.SOLUTION: A tight junction control agent comprising at least one selected from the compounds represented by formulas (1) to (4), or at least one selected from pharmaceutically acceptable salts of the compounds represented by formulas (1) to (4).SELECTED DRAWING: Figure 4

The invention discloses an application of a CTSS inhibitor in preparation of a medicine for regulating a blood-cerebrospinal fluid barrier. Wherein the CLDN1 between the CTSS in the CP and the CPECs is inversely correlated, then the CLDN1 is confirmed to be damaged after being processed by the CTSS, and correlation exists through CTSS-CLDN1-CP epithelial cell tight connection-CP aging, so that the CTSS can be applied to predict whether the CLDN1 is damaged and tightly connected or not, and then whether a B-CSF barrier is damaged or not or whether the B-CSF barrier is more permeable or not is detected.

The present invention discloses the preparation of patchouli flavonoid nanoliposomes and their application in inhalation treatment of acute lung injury, and relates to the field of medical technology. The patchouli flavonoid nanoliposomes provided by the present invention prepare patchouli flavonoids into a liposome dosage form, which has good stability and biocompatibility. The drug is administered to mice with acute lung injury, so that patchouli flavonoids can act on the mouse lungs in a targeted manner, reduce the expression of inflammatory factors such as IL-6, IL-1β and TNF-α in the mouse lungs to relieve inflammation, improve pulmonary edema, and reduce lung tissue damage, while increasing the levels of tight junction factors such as ZO-1, VE-Cadherin, E-Cadherin and Claudin5 to repair lung barrier damage. The present invention is expected to provide an effective strategy for the treatment of acute lung injury.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

The present application relates to the technical field of medicine, in particular to a kind of siRNA eye drop for penetrating mucus barrier and cell barrier and preparation method thereof.Innovative development side chain guanidino group-containing polydisulfide delivery carrier is used in the present application, through the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on mucin, tear film retention and efficient penetration are realized, and cationic polydisulfide is quickly adsorbed on the surface of negative charged cell membrane by electrostatic interaction, the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on cell membrane is used, and endocytosis is used to quickly penetrate tight junction cell layer.

The application discloses application of butyric acid in preparation of a medicine for treating oral ulcer, and belongs to the field of biological medicine. The butyric acid plays a therapeutic effect by increasing expression of tight junction proteins in oral mucosa tissue, reducing inflammatory reaction and promoting healing of oral ulcer. The application uses butyric acid to treat oral ulcer, evaluates the curative effect of butyric acid and explores the corresponding internal mechanism. The results show that the butyric acid has obvious effect in treating oral ulcer caused by chemotherapy, and provide a scientific basis for clinical application of butyric acid.

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The invention provides a pharmaceutical composition for protecting intestinal injury caused by chemotherapy and application, and belongs to the field of medicines. The invention also provides a pharmaceutical composition for protecting intestinal mucosa tight junction injury caused by chemotherapy. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-3 parts of astragalus polysaccharide and 1-3 parts of ziyuglycoside I. According to the invention, the compatibility of astragalus polysaccharide and ziyuglycoside I not only can improve the immunity of the organism after chemotherapy, but also can protect intestinal mucosal injury caused by intestinal chemotherapy drugs, and solves the problem that no special-effect drug for intestinal injury after chemotherapy exists in the current market, and pharmacodynamic tests prove that when the compatibility of astragalus polysaccharide and ziyuglycoside I is used, the curative effect is obvious. The intestinal mucosa tight junction injury caused by chemotherapy is protected, and the synergistic effect is achieved. The composition disclosed by the invention has the effects of protecting intestinal injury caused by pet chemotherapy or diarrhea of young animals, maintaining the integrity of the form and the structure of intestinal tissues, enhancing the immunity of the young animals, reducing the economic loss and reducing the use of antibiotics.

The application provides a pharmaceutical composition for protecting intestinal injury caused by chemotherapy and use, and belongs to the field of medicines. The application also provides a pharmaceutical composition for protecting tight junction injury of intestinal mucosa caused by chemotherapy, which is prepared from raw medicinal materials in the following proportions by weight: 1-3 parts of astragalus polysaccharide and 1-3 parts of sanguisorba officinalis saponin I. The astragalus polysaccharide combined with the sanguisorba officinalis saponin I can not only improve the immunity of the body after chemotherapy, but also protect the intestinal mucosa injury caused by intestinal chemotherapy drugs, and solves the problem that there is no specific drug for intestinal injury after chemotherapy on the market. The drug efficacy test proves that the astragalus polysaccharide combined with the sanguisorba officinalis saponin I has a synergistic effect on protecting the tight junction injury of intestinal mucosa caused by chemotherapy. The composition of the application can protect the intestinal injury of pets caused by chemotherapy or diarrhea of young animals, maintain the integrity of the intestinal tissue morphology and structure, enhance the immunity of young animals, reduce economic losses, and reduce the use of antibiotics.

This invention discloses a mixture of artemisia annua extract and rosemary extract and its application in the field of dermatology. The invention provides a mixture of artemisia annua extract and rosemary extract, a preparation method, and applications. This mixture can regulate the function of macrophages and epidermal cells, enhancing the phagocytic capacity of macrophages and initiating normal skin immune defense. Simultaneously, it can inhibit the overexpression of inflammatory factors, increase the expression of tight junction proteins in epidermal cells, and restore the skin barrier.

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.

The invention discloses an active substance for repairing a cat sensitization type barrier and a preparation method and application thereof, and relates to the technical field of animal health care products. The cat feed additive comprises one or more of heartleaf houttuynia herb extract, green tea polyphenol, ginkgo leaf extract, glutamine, beta-glucan, linoleic acid, vitamin B6, vitamin B2 and the like, and the components jointly act on oxidative stress, inflammatory response and metabolic process of intestinal tracts and skin of cats. By measuring indexes such as inflammatory factors, oxidative stress and tight junction protein and combining in-vitro metabonomics and transcriptomics analysis, the pharmaceutical composition has remarkable effects in the aspects of oxidation resistance, inflammation resistance, mucosal barrier repair and the like. In addition, the invention also provides application of the active substance in preparation of food for repairing cat barrier dysfunction. Compared with the prior art, an effective health-care strategy can be provided, and cat barrier dysfunction can be remarkably repaired.

The method is for modulating tight junction (TJ) integrity in a subject. The method comprises (a) evaluating TJ integrity in a subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering the subject a first composition containing (i) at least one polyphenol and (ii) a second substance, rather than a polyphenol, that upregulates CAMP gene expression in the subject; (c) re-evaluating TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of the at least one biomarker falls within the target range.

The present invention relates to a food composition comprising dead cells of Lactobacillus paracasei HY2782. The dead cells of Lactobacillus paracasei HY2782 of the present invention strengthens tight junctions, and thus can improve intestinal function.

The invention provides a collagen peptide-containing sebum membrane repairing composition and a preparation method thereof, and relates to the field of biomedical materials. The sebum film repairing composition is prepared from a recombinant III type collagen peptide, a recombinant I type collagen peptide, a ceramide compound, squalane, a natural moisturizing factor, glycosyl trehalose, phytosterol, glycerol, butanediol, polyglycerol-10 laurate, laurocapram and water. According to the sebum membrane repairing composition, the recombinant III-type collagen peptide and the recombinant I-type collagen peptide have a synergistic effect with the ceramide compound, so that the ceramide recovery rate is greatly improved, and the composition can realize'lipid barrier-aquaporin-tight connection 'three-in-one repairing of a sebum membrane.

The application discloses a recombinant virus-like nanoparticle for immunotherapy of gastric cancer and application thereof. The recombinant virus-like nanoparticle is a chimeric recombinant virus-like nanoparticle formed by self-assembly of a fusion protein HBC-CLDN18.2 of a hepatitis B virus core protein and CLDN18.2 tight junction protein. The application uses genetic engineering technology to truncate the C-terminal end of a natural hepatitis B virus core antigen, and mutate cysteine residues at positions 48 and 107 into serine, so that the hepatitis B virus core antigen can self-assemble into a virus-like nanoparticle with strong stability. The virus-like nanoparticle is used as a carrier, a B cell epitope peptide (tight junction protein CLDN18.2) of a gastric cancer tumor-related antigen is inserted into an immunodominant site of the carrier, so that the humoral immune response against gastric cancer is enhanced. Two T cell epitope peptides of the heterologous hepatitis B virus core antigen are used to replace T cell epitope peptides on the carrier, so that the cellular immune response against gastric cancer is enhanced, and strong antitumor effect and immune memory effect are shown.

The application discloses application of ginseng glycoprotein monomer in preparation of a medicine for treating intestinal inflammation, and belongs to the technical field of biological medicine. The ginseng glycoprotein monomer extracted by the application has a molecular weight of 27kDa, a total sugar content of 65.3±2.0%, and a total protein content of 29.9±0.2%. The ginseng glycoprotein monomer can effectively treat Caco-2 cell activity reduction, cell monolayer integrity reduction and inflammatory factor release caused by DSS, and restore tight junction protein ZO-1 and Occludin expression. Therefore, the ginseng glycoprotein monomer can be used for preparing an effective medicine for treating intestinal inflammation.

The invention provides a plant lactobacillus MLPCO23 resistant to PEDV (porcine epidemic diarrhea virus) infection and application of the plant lactobacillus MLPCO23, and belongs to the technical field of microorganisms. The preservation number of the plant lactobacillus MLPCO23 is CCTCC (China Center for Type Culture Collection) NO: M 20252370. The plant lactobacillus MLPCO23 can be colonized in intestinal tracts, has a remarkable PEDV (porcine epidemic diarrhea virus) resisting effect, and can be used for improving the PEDV infection resisting capability of piglets and relieving clinical symptoms caused by PEDV infection. The plant lactobacillus MLPCO23 can repair intestinal villi and close connection structures, increase the number of goblet cells and maintain the steady state of intestinal barriers. The plant lactobacillus MLPCO23 serving as intestinal probiotics provides a new intervention target and a prevention and control strategy for PEDV infection, and also provides a new thought and a new clue for clarification of the effect and mechanism of Min pig flora for regulating intestinal mucosa microecology and resisting PEDV infection.

The application relates to an oral drug delivery system with a double-emulsion structure and application thereof in preparation of a medicine for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises an oil-phase solvent, MSCs conditioned medium is wrapped in the inside to form a droplet particle, and exosomes are uniformly distributed on the outer surface of the droplet particle, thereby forming a double-emulsion structure. The water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that the water-soluble protein is absorbed into the human body in an oral mode. The application has good structural stability and viscoelasticity, the particle size range is about 10-50 mu m, the contact with the intestinal epithelial cells is facilitated, meanwhile, the skeleton of the intestinal epithelial cells can be changed, the expression of the tight junction protein of the intestinal epithelial cells is lowered, the tight junction barrier of the intestinal epithelial cells is opened, and therefore the bioavailability of the MSC-CM is improved, and the role of treating POI is played.

The invention discloses a semen euryales gel with an intestinal barrier repairing function and a preparation method of the semen euryales gel, and belongs to the field of medical biological materials. The preparation method comprises the following steps: drying and crushing Asiaocai fruits, carrying out ultrasonic extraction to obtain an Asiaocai extracting solution, preparing a composite solution from the Asiaocai extracting solution and additives such as sodium alginate or modified sodium alginate, finally dropwise adding the composite solution into a coagulating bath containing a divalent or trivalent metal ion cross-linking agent, and carrying out a cross-linking reaction to obtain the Asiaocai gel. According to the gel, a compact and stable three-dimensional network structure is constructed through the combined action of the semen euryales pectin and the modified polysaccharide, the gel has excellent mechanical strength, gastrointestinal tract degradation resistance and precise colon targeting performance, the intestinal barrier can be repaired through the dual mechanisms of reconstructing epithelial cell tight connection and repairing a mucous layer, and the intestinal tract targeting effect is improved. The symptoms of weight loss, colon shortening and the like of mice with acute colitis are remarkably improved, inflammatory cell infiltration is reduced, an efficient targeted delivery carrier is provided for treating inflammatory bowel diseases, and the application prospect is wide.

The invention belongs to the technical field of medicines, and provides a medicine capable of preventing and treating gastric ulcer. Evaluation of the acute gastric ulcer treatment effect of early chick embryo amniotic fluid finds that the early chick embryo amniotic fluid can reduce the gastric tissue ulcer area and inflammatory factor infiltration, and the protective effect of the mucosal barrier on the gastric tissue is enhanced by reducing the calcium ion content in the gastric tissue and myeloperoxidase, so that the gastric ulcer treatment effect is improved. In addition, the oxidative stress level caused by ethanol is obviously inhibited, and the level of tight junction protein of stomach tissue is up-regulated. The invention has the potential of treating gastric ulcer.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

The application discloses a Bifidobacterium longum subsp. longum strain for regulating intestinal homeostasis and relieving intractable constipation and an application thereof, and belongs to the field of microorganisms. The strain CCFM1319 provided by the application can shorten the time of the first black stool of intractable constipation mice, significantly enhance the colon peristalsis ability of the intractable constipation mice, increase the expression level of the characteristic marker of enteric glial cells in the colon tissue, repair the intestinal nerve damage caused by intractable constipation, reduce the expression level of inflammatory factors in the colon tissue of the intractable constipation mice, relieve the inflammation of the intestinal immune barrier, reduce the pathological damage of the colon tissue, increase the expression amount of the tight junction protein in the colon tissue, repair the damage of the intestinal mechanical barrier, avoid excessive water absorption, be beneficial to the excretion of feces, regulate the intestinal chemical barrier, improve the intestinal microecological imbalance, make the intestinal flora structure tend to be healthy, and repair the damage of the intestinal biological barrier, so as to play a role in comprehensively relieving intractable constipation.

The present application finds that ITIH4 secreted by macrophages can promote the viability and repair of intestinal epithelial cells, promote the expression of intestinal tight junction protein ZO-1, and inhibit the expression of macrophage inflammatory factors, and is an effective molecule for treating intestinal inflammation. Based on this, the present application provides the use of ITIH4 in the preparation of a medicament for treating intestinal inflammation.

The invention relates to lactobacillus amylovorans and an application thereof in intestinal diseases, the lactobacillus amylovorans (LA) is named as lactobacillus amylovorans QC1H, is preserved in China Center for Type Culture Collection on March 28, 2023, and has a preservation number of CCTCC NO: M2023427, the lactobacillus amylovorans and / or a fermentation product thereof can significantly improve the ratio of mouse intestinal villus length to crypt depth, and the lactobacillus amylovorans and / or the fermentation product thereof can significantly improve the intestinal villus length and crypt depth of mice. The compound has the advantages of reducing mouse ileum enteritis factor expression, improving ileum tight junction protein expression and reducing intestinal permeability, and has important application significance and value in preparation of a therapeutic agent for preventing and treating enteritis caused by aflatoxin B1 (AFB1).

The invention relates to the technical field of laying hen breeding feed, particularly discloses a feed additive for improving salpingitis and eggshell quality of laying hens in the later egg laying period and application of the feed additive, and aims to relieve the salpingitis of the laying hens in the later egg laying period and improve production performance and egg quality. The technical key points are as follows: when 200 mg / kg of ME or an equal amount of Rottlerin is added into the feed, mucosal lesion and inflammatory cell infiltration caused by salpingitis can be effectively relieved; specifically, swelling and bleeding of the fallopian tube are relieved, epithelial resistance of mucous membranes is improved, expression of tight junction protein is increased, and the level of inflammatory factors is reduced, so that the pathological state of the fallopian tube is remarkably improved; meanwhile, the additive significantly improves the laying rate and egg quality of the laying hens, especially the ultrastructure and strength of eggshells, reduces the feed-egg ratio, and optimizes the production performance of the laying hens. The additive disclosed by the invention can relieve inflammatory response, improve the health level of laying hens and reduce the use of medicines to a certain extent, so that the safe production of the laying hens is guaranteed, and the additive has important application value.

The application discloses a kind of film type L-arginine-alpha-ketoglutarate salt sustained-release particles and its preparation method and application.The sustained-release particles include internal core material and external wall material, internal core material is L-arginine-alpha-ketoglutarate salt, external wall material is homogeneous complex matrix of stearic acid and sodium alginate, and the mass ratio of core material and wall material is 7:3 to 8:2.The sustained-release particles are obtained by stearic acid-sodium alginate complex wall material cold spray coating L-arginine-alpha-ketoglutarate salt, realize the synergistic effect of gastric acid tolerance and intestinal target release.Under 0.75%-1.00% additive dose, the sustained-release particles can significantly repair fish intestinal physical barrier, up-regulate tight junction protein and oligopeptide transporter expression, reduce serum intestinal permeability markers, and simultaneously activate muscle mTOR signaling pathway, promote collagen deposition, reduce drip loss rate, and comprehensively improve fish intestinal health and muscle quality.

It is found that ITIH4 secreted by macrophages can promote intestinal epithelial cell activity and repair, promote expression of intestinal tight junction protein ZO-1 and inhibit expression of macrophage inflammatory factors and is an effective molecule for treating intestinal inflammation. On the basis, the invention provides application of ITIH4 in preparation of a medicine for treating enteritis.